Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

The brand name for the anti-diabetes compound semaglutide has broken all records by becoming one of the most profitable and ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

The rising prevalence of diabetes is anticipated to drive the expansion of the semaglutide market in the coming years.

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

Users on TikTok have touted the benefits of taking berberine supplements, claiming benefits for weight loss, heart health and more. Do you need them?

Liraglutide is not a bulk drug substance for which there is a 'clinical need' to compound," the company ... versions of its blockbuster GLP-1 drug semaglutide, which is marketed for weight loss ...

New analysis from GlobalData spans the growth of the heart failure market across seven major markets including the US, Europe ...

Semaglutide sells for $997 a month when branded under Ozempic and $1,349 a month for Wegovy. The haircut to Ozempic may have a spillover effect on competitor drugs from Eli Lilly — Mounjaro and ...